(These articles have been accepted for this issue. Change is possible before publication.)

    Volume 13, Number 9

EDITORIALS

ORIGINAL PAPERS

LUNG CANCER

LYMPHOMA

NEURO-ONCOLOGY

Regulatory Issues: FDA

SYMPTOM MANAGEMENT AND SUPPORTIVE CARE

LETTERS TO THE EDITOR

   EDITORIALS

Preserving the Sacred Bond: An Audit Must Be Performed

Bruce A. Chabner

One in Five Cancer Clinical Trials Are Published: A Terrible Symptom -- What’s the Diagnosis?

Gregory A. Curt and Bruce A. Chabner

Commentary: Practicing on the Tip of an Information Iceberg? Evidence of Underpublication of Registered Clinical Trials in Oncology

SCOTT RAMSEY, JOHN SCOGGINS

Commentary: Publishing Cancer Clinical Trial Results: A Scientific and Ethical Imperative

James H. Doroshow

Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?

THOMAS E. STINCHCOMBE, MARK A. SOCINSKI

Consensus Conference: Multimodality Management of Early- and Intermediate-Stage Non-Small Cell Lung Cancer

RODOLFO BORDONI

The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy

XUHUI ZHOU, WEIGUO HU, XUEBIN QIN

Neoplastic Meningitis

MARC C. CHAMBERLAIN

Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors

AHMED IDBAIH, FRANÇOIS DUCRAY, MONICA SIERRA DEL RIO, KHÊ HOANG-XUAN, JEAN-YVES DELATTRE

FDA Report: Eculizumab (Soliris®) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

Andrew Dmytrijuk, Kathy Robie-Suh, Martin H. Cohen, Dwaine Rieves, Karen Weiss, Richard Pazdur

Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib

MARIO E. LACOUTURE, SHENHONG WU, CAROLINE ROBERT, MICHAEL B. ATKINS, HEIDI H. KONG, JOAN GUITART, CLAUS GARBE, AXEL HAUSCHILD, IGOR PUZANOV, DORU T. ALEXANDRESCU, ROGER T. ANDERSON, LAURA WOOD, JANICE P. DUTCHER

Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial

KERRY S. COURNEYA, LEE W. JONES, CAROLYN J. PEDDLE, CHRISTOPHER M. SELLAR, TONY REIMAN, ANIL A. JOY, NEIL CHUA, LINDA TKACHUK, JOHN R. MACKEY

Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

FAIROOZ F. KABBINAVAR, JOEL F. WALLACE, ERIC HOLMGREN, JING YI, DAVID CELLA, KATHLEEN J. YOST, HERBERT I. HURWITZ

Response to “CT Screening for Lung Cancer: Update 2007”

Peter B. Bach

In Reply

Claudia I. Henschke